从瓣膜病管理指南变迁看经导管主动脉瓣置换术领域的未知和探索方向  

The unknown and exploring areas of transcatheter aortic valve replacement from the perspective of changes in management guidelines for valvular disease

作　　者：陈莎莎 潘文志 周达新 葛均波 CHEN Sha-sha;PAN Wen-zhi;ZHOU Da-xin;Ge Jun-bo(Department of Cardiology,Zhongshan Hospital,Fudan University,Research Unit of Cardiovascular Techniques and Devices,Chinese Academy of Medical Sciences,National Clinical Research Center for Interventional Medicine,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院心内科,中国医学科学院心血管技术与器械创新单元,国家放射与治疗临床医学研究中心,上海200032

出　　处：《内科急危重症杂志》2021年第6期441-447,共7页Journal of Critical Care In Internal Medicine

基　　金：国家重点研发计划(No:2020YFC2008100)。

摘　　要：最新欧美瓣膜病管理指南对经导管主动脉瓣置换术(TAVR)的推荐越发积极,心脏团队的关注点逐渐从危险分层转移到患者年龄、人工瓣膜耐久性、解剖适应程度和技术成熟度。不难看出,TAVR的未知和挑战主要集中在瓣膜耐久性、TAVR的解剖适应证、冠脉通路和单纯主动脉瓣返流等方面。这正是我们在该领域进行更深入探索的方向。The latest European and American valvular heart disease management guidelines have become more positive in recommending transcatheter aortic valve replacement(TAVR),and the focus of heart team has gradually shifted from risk stratification to other aspects such as patients'age,prosthetic valve durability,anatomical suitability and technical maturity.It is not difficult to see that the unknown and challenges of TAVR mainly focus on valve durability,anatomical indications of TAVR,coronary access and pure aortic valve regurgitation.That's where we are going to explore this more.

关 键 词：经导管主动脉瓣置换术 瓣膜耐久性 二叶式主动脉瓣 冠脉阻塞 主动脉瓣返流 

分 类 号：R542.5[医药卫生—心血管疾病] R654.2[医药卫生—内科学]